Bolt Biotherapeutics Q3 2022 operating loss $22.3M; cash $209.6M funds through 2025

Bolt Biotherapeutics, Inc.

2022-Q3 EPS reported -$1.83 revenue$4,318,000

Cash $209.6M as of Sep 30, 2022; expected to fund operations and milestones through 2025.
BDC-1001 dose-escalation trial on track to complete enrollment by year-end; topline data and RP2D expected Q1 2023.
BDC-3042 IND-enabling progressing; on track for clinical entry in 2023.
Collaboration revenue $2.1M (up from $0.8M YoY); R&D expense $19.0M, G&A $5.5M.
Loss from operations $22.3M vs $23.5M in Q3 2021.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bolt Biotherapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $2.1 million.

Period: third quarter ended September 30, 2022
Revenue: $2.1 million
Result: reported results

Exact text from the filing

16th, 2022, with a corporate presentation at 1:15 p.m. ET in New York, New York. Third Quarter 2022 Financial Results • Collaboration Revenue – Collaboration revenue was $2.1 million for the third quarter ended September 30, 2022, compared to $0.8 million for the same quarter in 2021. This represents 50% growth over the second quarter of 2022 as Bolt

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024476

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.